PT - JOURNAL ARTICLE AU - Tongai G Maponga AU - Anna L McNaughton AU - Marije Van Schalkwyk AU - Susan Hugo AU - Chikezie Nwankwo AU - Jantjie Taljaard AU - Jolynne Mokaya AU - David A Smith AU - Cloete van Vuuren AU - Dominique Goedhals AU - Shiraaz Gabriel AU - Monique I Andersson AU - Wolfgang Preiser AU - Christo van Rensburg AU - Philippa C Matthews TI - Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort AID - 10.1101/19007963 DP - 2019 Jan 01 TA - medRxiv PG - 19007963 4099 - http://medrxiv.org/content/early/2019/12/19/19007963.short 4100 - http://medrxiv.org/content/early/2019/12/19/19007963.full AB - Objective Prompted by international targets for elimination of hepatitis B virus (HBV) infection, we performed a cross-sectional observational study of adults with chronic HBV (CHB) infection in South Africa, characterising individuals with HBV monoinfection vs. those coinfected with HBV/HIV, to evaluate the impact of therapy and to guide improvements in clinical care as guidelines for antiviral therapy change over time.Design We prospectively recruited 115 adults with CHB, over a period of one year at a university hospital in Cape Town, South Africa. HIV coinfection was present in 39 (34%) subjects. We recorded cross-sectional demographic, clinical and laboratory data.Results Adults with HBV monoinfection were comparable to those with HBV/HIV coinfection in terms of age, sex and body mass. HBeAg-positive status was more common among those with HIV coinfection (p=0.01). However, compared to HBV/HIV coinfection, HBV monoinfected patients were less likely to have had assessment with elastography (p<0.0001) and less likely to be on antiviral treatment (p<0.0001). The HBV monoinfected group was more likely to have detectable HBV viraemia (p=0.04), and features suggesting underlying liver disease including moderate/severe thrombocytopaenia (p=0.007), elevated bilirubin (p=0.004), and APRI score >2 (p=0.02). Three cases of hepatocellular carcinoma were documented, all in patients with HBV monoinfection.Conclusion In this setting, individuals with HBV monoinfection are disadvantaged in terms of clinical assessment and appropriate antiviral therapy compared to those with HIV coinfection, associated with relatively worse liver health. Enhanced advocacy, education, resources and infrastructure are required to optimise interventions for CHB.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Wellcome Trust (grant ref 110110).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll data referred to in the manuscript are available as supplementary files (links provided in manuscript). https://figshare.com/s/756eff7c317ef041cf0e